Your shopping cart is currently empty

Peldesine (BCX 34) is an effective, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase. Peldesine inhibits T-cell proliferation with an IC50 of 800 nM. Peldesine can be used in research on cutaneous T-cell lymphoma, psoriasis and HIV infection.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $116 | In Stock | In Stock | |
| 5 mg | $289 | In Stock | In Stock | |
| 10 mg | $463 | In Stock | In Stock | |
| 25 mg | $766 | In Stock | In Stock | |
| 50 mg | $1,070 | In Stock | In Stock | |
| 100 mg | $1,450 | In Stock | In Stock | |
| 500 mg | $2,880 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $318 | In Stock | In Stock |
| Description | Peldesine (BCX 34) is an effective, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase. Peldesine inhibits T-cell proliferation with an IC50 of 800 nM. Peldesine can be used in research on cutaneous T-cell lymphoma, psoriasis and HIV infection. |
| Targets&IC50 | RBC PNP (mouse):32 nM , PNP (rat red blood cells):5 nM , RBC PNP (human):36 nM , Proliferation (human T cells):800 nM |
| In vitro | The IC50s are 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell purine nucleoside phosphorylase, respectively. In Jurkat cells, Peldesine (BCX 34; 0-50 µM; 72 hours) inhibits the T-cell proliferation completely at a concentration of less than 10 μM, in the presence of dGuo (10 μM). In contrast, the B-cell proliferation is not affected by Peldesine[1]. |
| In vivo | Peldesine demonstrates oral efficacy by elevating plasma inosine levels in rats (2-fold at 30 mg/kg), significantly reducing ex vivo red blood cell (RBC) purine nucleoside phosphorylase (PNP) activity in rats (98% at 3 hours, 100 mg/kg), and moderately suppressing ex vivo skin PNP activity in mice (39% at 3 hours, 100 mg/kg). Additionally, Peldesine exhibits an oral bioavailability of 76% in rats[2]. |
| Synonyms | BCX 34 |
| Molecular Weight | 241.25 |
| Formula | C12H11N5O |
| Cas No. | 133432-71-0 |
| Smiles | C(C=1C2=C(NC1)C(=O)N=C(N)N2)C=3C=CC=NC3 |
| Relative Density. | 1.57g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 195 mg/mL (808.29 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (20.73 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.